Formoterol porous particle

Drug Profile

Formoterol porous particle

Alternative Names: FF MDI; Porous particle formoterol fumarate; PT-005

Latest Information Update: 30 Sep 2016

Price : $50

At a glance

  • Originator Pearl Therapeutics
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 30 Sep 2016 Discontinued - Phase-III for Chronic obstructive pulmonary disease in Australia, New Zealand, USA (Inhalation)
  • 01 Mar 2015 Pearl Therapeutics completes a phase II trial for Chronic obstructive pulmonary disease in USA (NCT02196077)
  • 01 Mar 2015 Pearl Therapeutics completes the PINNACLE 3 trial in Chronic obstructive pulmonary disease in USA, Australia and New Zealand (NCT01970878)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top